CXCR3 and acute lymphoblastic leukemia: Accordingly, the adhesion of T-ALL cells was reduced upon treatment with a CXCR3 antagonist or CXCL10 neutralizing antibody compared with untreated or control leukemic cells (Supplemental Figure 7, E and F).